DROXIDOPA Chemical Properties

Melting point:

232-235° (dec); mp 229-232° (dec) (Ohashi)

alpha 

D20 -39° (c = 1 in 1N aq HCl); D20 -42.0° (c = 1 in 1N aq HCl)

Boiling point:

549.8±50.0 °C(Predicted)

Density 

1.608±0.06 g/cm3(Predicted)

storage temp. 

-20°C

solubility 

DMSO: ≥3mg/mL

form 

powder

pka

2.09±0.24(Predicted)

color 

white to tan

Merck 

14,3457

Stability:

Hygroscopic

CAS DataBase Reference

23651-95-8

Safety Information

Hazard Codes 

Xi

Risk Statements 

36/37/38

Safety Statements 

26

WGK Germany 

3

RTECS 

VT9626010

HS Code 

29225090

DROXIDOPA Usage And Synthesis

Description

Droxidopa is a synthetic amino acid precursor of (-)-norepinephrine which is absorbed from the gut and metabolized to norepinephrine. In Parkinsonian patients, droxidopa added to existing levodopa/decarboxylase inhibitor therapy produces significant improvements in retropulsion, dysarthria and muscular rigidity refractory to other treatments; however, tremor was unaffected.

Description

Droxidopa (L-DOPS) is a synthetic precursor and prodrug of the neurotransmitter norepinephrine. It is transformed into norepinephrine through the action of DOPA decarboxylase. L-DOPS increases norepinephrine levels in the rat heart following intraperitoneal administration and in the brain following intracerebroventricular administration at doses of 125 and 100 μg/animal, respectively. It increases arterial pressure and mesenteric arterial resistance in rats with ligated portal vein or biliary ducts when used at doses of 25-50 mg/kg. L-DOPS crosses the blood brain barrier, however, its effects can be blocked by the peripherally-restricted DOPA decarboxylase inhibitor carbidopa , indicating that the mechanism is peripheral. Formulations containing droxidopa are used in the treatment of neurogenic orthostatic hypotension.

Chemical Properties

Off-White Solid

Originator

Sumitomo (Japan)

Uses

The L-threo-form Droxidopa. A synthetic amino acid precursor of Norepinephrine (N674500). Antiparkinsonian.

Uses

Droxidopa is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline).

Uses

L-DOPS has been administered for clinical trial studies in mice with amyloid pathology.

Definition

ChEBI: A serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension

brand name

DOPS

General Description

L-DOPS, also called L-threo 3,4-Dihydroxyphenylserine or droxidopa is a catecholamine. L-DOPS has many clinical advantages and may be useful for treating norepinephrine deficiency. It is used for treating neurogenic orthostatic hypotension and improves norepinephrine levels. L-DOPS mediates reduction of amyloid plaques and could have a therapeutic potential for treating amyloid pathology.

Biochem/physiol Actions

L-DOPS is a norepinephrine precursor in vivo.

DROXIDOPA(23651-95-8)Related Product Information

• Nitazoxanide
• VILAZODONE
• Miglitol
• alpha,2-Dimethyl-5-nitro-1H-imidazole-1-ethanol
• Chrysene
• Dihydrocaffeic acid
• L-M-TYROSINE
• Levodopa
• 3-(3-Hydroxyphenyl)-DL-alanine
• 3-Phenyl-L-serine
• (2RS,3RS)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-3-HYDROXY-PROPIONIC ACID
• DROXIDOPA
• DL-THREO-3-PHENYLSERINE HYDRATE, 99
• (S)-3-HYDROXY-3-PHENYLPROPANOIC ACID
• DL-THREO-3-PHENYLSERINE
• BOC-D-THREO-3-(3,4-DIMETHOXYPHENYL)SERINE
• DL-BETA-PHENYLSERINE THREO FORM
• BOC-D-THREO-3-(BENZO[1,3]DIOXOL-5-YL)SERINE